Fitzroy W. Dawkins

Hemochromatosis and Iron-Overload Screening in a Racially Diverse Population

Paul C. Adams, David M. Reboussin, James C. Barton et al. · New England Journal of Medicine · 2005 · 758 citations · Full text

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers et al. · Investigational New Drugs · 2012 · 389 citations

Cnto 888, Medicine, Human Monoclonal Antibody +8

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Madan Jagasia, Miguel‐Angel Perales, Mark A. Schroeder et al. · Blood · 2020 · 289 citations · Full text

Enrollment of African Americans Onto Clinical Treatment Trials: Study Design Barriers

Lucile L. Adams‐Campbell, Chiledum Ahaghotu, Melvin Gaskins et al. · Journal of Clinical Oncology · 2004 · 198 citations · Full text

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

Svetomir N. Markovic, Susan M. Geyer, Fitzroy W. Dawkins et al. · Cancer · 2005 · 130 citations · Full text